Advertisement

Long-term outcomes of diabetes after laparoscopic Roux-en-Y gastric bypass in a Lebanese bariatric practice

  • Mohamad A. Minhem
  • Ramzi S. Alami
  • Bassem Y. SafadiEmail author
Original Article
  • 2 Downloads

Abstract

Introduction

Roux-Y-gastric bypass (RYGB) is highly effective in treating obesity related type II diabetes mellitus (DM). There are a few studies from the Middle East and North Africa (MENA) on the impact of RYGB on DM.

Objective

The aim of our study was to evaluate the impact of RYGB on DM in our patient population.

Methods

We retrospectively reviewed our database and selected obese patients with type II DM who underwent primary laparoscopic RYGB from 2005 to 2015. Complete remission (CR) of DM was defined as HbA1c < 5.7%, FBG < 100 mg/dL without medications. Partial remission (PR) was defined as HbA1c 5.7–6.4%, FBG 100–125 mg/dL without medications. Improvement was defined by a significant reduction in HbA1c (> 1%) or FBG (> 25 mg/dL) or reduction in HbA1c and FBG accompanied by discontinuing insulin.

Results

Out of 245 RYGB patients, 107 had DM. In comparison, diabetic patients were older and had more hypertension and dyslipidemia. At 5 years with a follow-up (F/U) of 56%, total weight loss in diabetics (24.7%) was lower than non-diabetics (27.7%). At a mean F/U of 5.6 ± 2.7 years, range (1.4 to 10.7), there was a significant reduction in HbA1C (7.9 to 6.1%), FBG (158 to 111 mg/dL), intake of oral hypoglycemic (73.6 to 29.7%), as well as insulin therapy (15.4 to 2.2%). The rate of DM CR was 42.3%, PR 20.5%, improvement 23.1%, and no change 14.1%.

Conclusion

This is the first report from the MENA region on the long-term outcomes of RYGB in the treatment of type II DM. The results are similar to those in the international literature.

Keywords

Gastric bypass Diabetes Remission Long-term Lebanon 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.  https://doi.org/10.1016/j.diabres.2013.11.002.CrossRefGoogle Scholar
  2. 2.
    Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51.  https://doi.org/10.1056/NEJMoa1600869.CrossRefGoogle Scholar
  3. 3.
    Ikramuddin S, Korner J, Lee W, et al. Roux-en-y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA. 2013;309(21):2240–9.  https://doi.org/10.1001/jama.2013.5835.CrossRefGoogle Scholar
  4. 4.
    Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304.  https://doi.org/10.1001/jama.2014.5988.CrossRefGoogle Scholar
  5. 5.
    Espinosa O, Pineda O, Maydon HG, Sepulveda EM, Guilbert L, Amado M, et al. Type 2 diabetes mellitus outcomes after laparoscopic gastric bypass in patients with BMI <35 kg/m(2) using strict remission criteria: early outcomes of a prospective study among Mexicans. Surg Endosc. 2018;32(3):1353–9.  https://doi.org/10.1007/s00464-017-5815-3.CrossRefGoogle Scholar
  6. 6.
    Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55.  https://doi.org/10.1056/NEJMoa1700459.CrossRefGoogle Scholar
  7. 7.
    Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266(4):650–7.  https://doi.org/10.1097/SLA.0000000000002407.CrossRefGoogle Scholar
  8. 8.
    Obeid NR, Malick W, Concors SJ, Fielding GA, Kurian MS, Ren-Fielding CJ. Long-term outcomes after Roux-en-Y gastric bypass: 10- to 13-year data. Surg Obes Relat Dis. 2016;12(1):11–20.  https://doi.org/10.1016/j.soard.2015.04.011.CrossRefGoogle Scholar
  9. 9.
    Jimenez A, Casamitjana R, Flores L, Viaplana J, Corcelles R, Lacy A, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9.  https://doi.org/10.1097/SLA.0b013e318262ee6b.CrossRefGoogle Scholar
  10. 10.
    Almalki OM, Lee W-J, Chong K, Ser K-H, Lee Y-C, Chen S-C. Laparoscopic gastric bypass for the treatment of type 2 diabetes: a comparison of Roux-en-Y versus single anastomosis gastric bypass. Surg Obes Relat Dis. 2018;14(4):509–15.  https://doi.org/10.1016/j.soard.2017.12.022.CrossRefGoogle Scholar
  11. 11.
    Costanian C, Bennett K, Hwalla N, Assaad S, Sibai AM. Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: findings from a national population-based study. Diabetes Res Clin Pract. 2014;105(3):408–15.  https://doi.org/10.1016/j.diabres.2014.06.005.CrossRefGoogle Scholar
  12. 12.
    Alzaman N, Ali A. Obesity and diabetes mellitus in the Arab world. J Taibah Univ Med Sci. 2016;11(4):301–9.  https://doi.org/10.1016/j.jtumed.2016.03.009.Google Scholar
  13. 13.
    Abusnana S, Abdi S, Tagure B, Elbagir M, Maleckas A. Bariatric surgery outcomes: a single-center study in the United Arab Emirates. Diabetes Metab Syndr Obes. 2015;8:461–71.Google Scholar
  14. 14.
    Taha O, Abdelaal M, Abozeid M, Askalany A, Alaa M. Outcomes of one anastomosis gastric bypass in 472 diabetic patients. Obes Surg. 2017;27(11):2802–10.  https://doi.org/10.1007/s11695-017-2711-9.CrossRefGoogle Scholar
  15. 15.
    Al-Sabah S, Almazeedi S, Alosaimi S, Al-Mulla A, Ali D, Al-Elewah A, et al. Remission of type 2 diabetes mellitus after laparoscopic sleeve gastrectomy. World J Lap Surg. 2014;7(3):121–4.  https://doi.org/10.5005/jp-journals-10033-1231.Google Scholar
  16. 16.
    Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.  https://doi.org/10.2337/dc09-9036.CrossRefGoogle Scholar
  17. 17.
    Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg D, Rogers A, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506.  https://doi.org/10.1016/j.soard.2015.02.003.CrossRefGoogle Scholar
  18. 18.
    Aminian A, Brethauer SA, Andalib A, Punchai S, Mackey J, Rodriguez J, et al. Can sleeve gastrectomy "cure" diabetes? Long-term metabolic effects of sleeve gastrectomy in patients with type 2 diabetes. Ann Surg. 2016;264(4):674–81.  https://doi.org/10.1097/SLA.0000000000001857.CrossRefGoogle Scholar
  19. 19.
    Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA. 2015;314(10):1052–62.  https://doi.org/10.1001/jama.2015.9536.CrossRefGoogle Scholar
  20. 20.
    Khorgami Z, Shoar S, Andalib A, Aminian A, Brethauer SA, Schauer PR. Trends in utilization of bariatric surgery, 2010-2014: sleeve gastrectomy dominates. Surg Obes Relat Dis. 2017;13(5):774–8.  https://doi.org/10.1016/j.soard.2017.01.031.CrossRefGoogle Scholar
  21. 21.
    Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg. 2008;12(2):250–5.  https://doi.org/10.1007/s11605-007-0427-1.CrossRefGoogle Scholar
  22. 22.
    de Hollanda A, Ruiz T, Jimenez A, Flores L, Lacy A, Vidal J. Patterns of weight loss response following gastric bypass and sleeve gastrectomy. Obes Surg. 2015;25(7):1177–83.  https://doi.org/10.1007/s11695-014-1512-7.CrossRefGoogle Scholar
  23. 23.
    Kadera BE, Lum K, Grant J, Pryor AD, Portenier DD, DeMaria EJ. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5(3):305–9.  https://doi.org/10.1016/j.soard.2009.02.007.CrossRefGoogle Scholar
  24. 24.
    Chen J-C, Hsu N-Y, Lee W-J, Chen S-C, Ser K-H, Lee Y-C. Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. Surg Obes Relat Dis. 2018;14:640–5.  https://doi.org/10.1016/j.soard.2018.01.027.CrossRefGoogle Scholar
  25. 25.
    Aminian A, Chang J, Brethauer SA, Kim JJ. ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m(2)). Surg Obes Relat Dis. 2018;14(8):1071–87.  https://doi.org/10.1016/j.soard.2018.05.025.CrossRefGoogle Scholar
  26. 26.
    Magouliotis DE, Tasiopoulou VS, Tzovaras G. One anastomosis gastric bypass versus Roux-en-Y gastric bypass for morbid obesity: a meta-analysis. Clin Obes. 2018;8(3):159–69.  https://doi.org/10.1111/cob.12246.CrossRefGoogle Scholar
  27. 27.
    Carlsson LM, Peltonen M, Ahlin S, Anveden A, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–704.  https://doi.org/10.1056/NEJMoa1112082.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2019

Authors and Affiliations

  • Mohamad A. Minhem
    • 1
  • Ramzi S. Alami
    • 1
  • Bassem Y. Safadi
    • 1
    Email author
  1. 1.Department of SurgeryAmerican University of Beirut Medical CenterBeirutLebanon

Personalised recommendations